Evidence Summary Table for Denosumab versus Bisphosphonates
| Denosumab vs Bisphosphonates | |||||
|---|---|---|---|---|---|
| Outcomes | Illustrative Comparative Risks* (95% CI) | Odds Ratio (OR) (95% CI) | Number of Participants (Studies) | Quality of the Evidence (GRADE) | |
| Assumed Risk [Bisphosphonate] | Corresponding Risk [Denosumab] | ||||
| Clinical fractures | [26] per 1000 | [29] per 1000 (21 to 42) | OR [1.12] (0.79 to 1.61) | [4635] (7) | ⊕⊕⊕⊝ moderate |
| Osteoporotic fractures | [17] per 1000 | [19] per 1000 (12 to 29) | OR [1.11] (0.71 to 1.73) | [4635] (7) | ⊕⊕⊕⊝ moderate |
↵*The basis for the assumed risk is the rate of events in the bisphosphonate group. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the odds ratio of the intervention (and its 95% CI).
GRADE, Working Group grades of evidence: high quality—further research is very unlikely to change our confidence in the estimate of effect; moderate quality—further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate: low quality—further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality—we are very uncertain about the estimate.